These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 39267969)

  • 1. SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages.
    Barrera A; Martínez-Valdebenito C; Angulo J; Palma C; Hormazábal J; Vial C; Aguilera X; Castillo-Torres P; Pardo-Roa C; Balcells ME; Nervi B; Corre NL; Ferrés M
    Front Med (Lausanne); 2024; 11():1414331. PubMed ID: 39267969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity.
    Kuzmina A; Korovin D; Cohen Lass I; Atari N; Ottolenghi A; Hu P; Mandelboim M; Rosental B; Rosenberg E; Diaz-Griffero F; Taube R
    Heliyon; 2023 Jun; 9(6):e16750. PubMed ID: 37292300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco.
    Djorwé S; Malki A; Nzoyikorera N; Nyandwi J; Zebsoubo SP; Bellamine K; Bousfiha A
    Access Microbiol; 2024; 6(10):. PubMed ID: 39376591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
    Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
    Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
    Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.
    Chatterjee S; Bhattacharya M; Nag S; Dhama K; Chakraborty C
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
    Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.